Harrow Health Inc (HROW) - Net Assets
Based on the latest financial reports, Harrow Health Inc (HROW) has net assets worth $46.66 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($363.07 Million) and total liabilities ($316.41 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Harrow Health Inc (HROW) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $46.66 Million |
| % of Total Assets | 12.85% |
| Annual Growth Rate | 49.11% |
| 5-Year Change | 158.3% |
| 10-Year Change | N/A |
| Growth Volatility | 3930.72 |
Harrow Health Inc - Net Assets Trend (2005–2024)
This chart illustrates how Harrow Health Inc's net assets have evolved over time, based on quarterly financial data. Also explore Harrow Health Inc balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Harrow Health Inc (2005–2024)
The table below shows the annual net assets of Harrow Health Inc from 2005 to 2024. For live valuation and market cap data, see Harrow Health Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $69.30 Million | -1.01% |
| 2023-12-31 | $70.00 Million | +160.38% |
| 2022-12-31 | $26.89 Million | +145.95% |
| 2021-12-31 | $10.93 Million | -59.26% |
| 2020-12-31 | $26.83 Million | -2.15% |
| 2019-12-31 | $27.42 Million | +10.78% |
| 2018-12-31 | $24.75 Million | +846.50% |
| 2017-12-31 | $2.62 Million | -59.34% |
| 2016-12-31 | $6.43 Million | +564.40% |
| 2015-12-31 | $-1.39 Million | -116.99% |
| 2014-12-31 | $8.15 Million | -46.06% |
| 2013-12-31 | $15.11 Million | +51.16% |
| 2012-12-31 | $10.00 Million | +688.02% |
| 2011-12-31 | $-1.70 Million | -63.74% |
| 2010-12-31 | $-1.04 Million | -279.87% |
| 2009-12-31 | $577.21K | -87.37% |
| 2008-12-31 | $4.57 Million | +30.98% |
| 2007-12-31 | $3.49 Million | +16247.32% |
| 2006-12-31 | $21.35K | -38.98% |
| 2005-12-31 | $34.99K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Harrow Health Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15133879400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $35.00K | 0.05% |
| Other Components | $221.00 Million | 317.29% |
| Total Equity | $69.65 Million | 100.00% |
Harrow Health Inc Competitors by Market Cap
The table below lists competitors of Harrow Health Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mader Group Ltd
AU:MAD
|
$1.14 Billion |
|
Astec Industries Inc
NASDAQ:ASTE
|
$1.14 Billion |
|
Meren Energy Inc.
NASDAQ:MRNFF
|
$1.14 Billion |
|
Bega Cheese Ltd
AU:BGA
|
$1.14 Billion |
|
Arbor Realty Trust
NYSE:ABR
|
$1.14 Billion |
|
China Railway Tielong Container Logistics Co Ltd
SHG:600125
|
$1.14 Billion |
|
Astra Microwave Products Limited
NSE:ASTRAMICRO
|
$1.14 Billion |
|
Stepan Company
NYSE:SCL
|
$1.14 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Harrow Health Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 70,357,000 to 69,652,000, a change of -705,000 (-1.0%).
- Net loss of 17,481,000 reduced equity.
- Other comprehensive income increased equity by 409,000.
- Other factors increased equity by 16,367,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-17.48 Million | -25.1% |
| Other Comprehensive Income | $409.00K | +0.59% |
| Other Changes | $16.37 Million | +23.5% |
| Total Change | $- | -1.00% |
Book Value vs Market Value Analysis
This analysis compares Harrow Health Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 15.80x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 10756.73x to 15.80x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $0.00 | $30.86 | x |
| 2006-12-31 | $0.24 | $30.86 | x |
| 2007-12-31 | $15.78 | $30.86 | x |
| 2008-12-31 | $12.34 | $30.86 | x |
| 2009-12-31 | $1.48 | $30.86 | x |
| 2011-12-31 | $-4.27 | $30.86 | x |
| 2012-12-31 | $2.22 | $30.86 | x |
| 2013-12-31 | $1.75 | $30.86 | x |
| 2014-12-31 | $0.89 | $30.86 | x |
| 2015-12-31 | $-0.14 | $30.86 | x |
| 2016-12-31 | $0.50 | $30.86 | x |
| 2017-12-31 | $0.13 | $30.86 | x |
| 2018-12-31 | $1.04 | $30.86 | x |
| 2019-12-31 | $1.05 | $30.86 | x |
| 2020-12-31 | $1.05 | $30.86 | x |
| 2021-12-31 | $0.42 | $30.86 | x |
| 2022-12-31 | $0.99 | $30.86 | x |
| 2023-12-31 | $2.16 | $30.86 | x |
| 2024-12-31 | $1.95 | $30.86 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Harrow Health Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -25.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -8.76%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 5.58x
- Recent ROE (-25.10%) is above the historical average (-265.25%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -132.04% | 0.00% | 0.00x | 1.14x | $-49.71K |
| 2006 | -2716.37% | 0.00% | 0.00x | 1.18x | $-582.14K |
| 2007 | -122.76% | 0.00% | 0.00x | 1.21x | $-4.63 Million |
| 2008 | -72.27% | 0.00% | 0.00x | 1.17x | $-3.76 Million |
| 2009 | -788.97% | 0.00% | 0.00x | 2.90x | $-4.61 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-784.00K |
| 2012 | -53.86% | -5384.00% | 0.01x | 1.07x | $-6.38 Million |
| 2013 | -50.58% | -76431.24% | 0.00x | 1.04x | $-9.15 Million |
| 2014 | -124.14% | -609.52% | 0.16x | 1.26x | $-10.93 Million |
| 2015 | 0.00% | -163.64% | 0.69x | 0.00x | $-15.76 Million |
| 2016 | -296.75% | -95.71% | 0.73x | 4.24x | $-19.73 Million |
| 2017 | -458.32% | -44.76% | 1.12x | 9.15x | $-12.25 Million |
| 2018 | 59.09% | 35.35% | 0.84x | 2.00x | $12.15 Million |
| 2019 | 0.61% | 0.33% | 0.87x | 2.13x | $-2.60 Million |
| 2020 | -12.35% | -6.87% | 0.85x | 2.11x | $-6.08 Million |
| 2021 | -159.55% | -24.85% | 0.74x | 8.71x | $-19.14 Million |
| 2022 | -51.71% | -15.90% | 0.56x | 5.76x | $-16.81 Million |
| 2023 | -34.70% | -18.75% | 0.42x | 4.43x | $-31.45 Million |
| 2024 | -25.10% | -8.76% | 0.51x | 5.58x | $-24.45 Million |
Industry Comparison
This section compares Harrow Health Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $234,430,838
- Average return on equity (ROE) among peers: -7.36%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Harrow Health Inc (HROW) | $46.66 Million | -132.04% | 6.78x | $1.14 Billion |
| Aurora Cannabis Inc (ACB) | $1.68 Million | -10.54% | 0.00x | $189.98 Million |
| Akanda Corp (AKAN) | $-2.20 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $-30.58 Million | 0.00% | 0.00x | $302.70 Million |
| Alkermes Plc (ALKS) | $419.23 Million | -9.45% | 0.24x | $4.62 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $433.43 Million | 11.37% | 0.19x | $1.53 Billion |
| Amphastar P (AMPH) | $448.72 Million | 0.31% | 0.41x | $784.90 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $896.36 Million | -18.93% | 3.86x | $3.81 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-186.87 Million | 0.00% | 0.00x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $5.80 Million | -34.48% | 0.38x | $205.57 Million |
| ANI Pharmaceuticals Inc (ANIP) | $358.74 Million | -11.88% | 1.15x | $1.78 Billion |
About Harrow Health Inc
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, … Read more